ALVIMEDICA announces to have received the CE mark of Cre8™ EVO 2.00mm to further enlarge the portfolio of its innovative polymer-free Amphilimus™ eluting stent.
Alvimedica, today, is able to offer physicians a more extensive treatment coverage for all those patients with complex coronary artery disease: Cre8™ EVO 2.0mm embeds the unique technologies of Cre8™ and Cre8™ EVO Drug Eluting Stents (DES) extending their clinical benefits to small vessels up to 2.0mm.
In the latest decades small vessel disease has become more frequent due to a worsening of the clinical profile of the patients undergoing Percutaneous Coronary Intervention (PCI): the population needing DES to treat coronary artery disease is everyday older, often with diabetes mellitus and with many comorbidities. These clinical conditions increase lesion complexity and consequently also the need of implanting DES in coronary arteries smaller than 2.25mm, which is usually the smallest available diameter in a DES coronary portfolio.
The Cre8™ EVO small vessel DES has a dedicated design which maximizes device performance in this clinical setting. The ultra-thin total stent struts of only 70 micron minimize metal volume in small coronaries, while the dedicated design matches the specific requirements of 2.00mm vessels in terms of device deliverability, conformability to the vessel and mechanical performances. Cre8™ EVO for small vessel is a "physician-friendly" device with no compromises. Its unique cell geometry allows this DES to be implanted in challenging conditions like tapered and tortuous vessels that can also involve clinically impactful sidebranches.
Leyla Alaton, president and CEO of Alvimedica, commented: "We are taking the challenge to develop devices that answer the real everyday clinical un-met needs in a global scenario. The patient population suffering from coronary disease increases every year, as well as its clinical need may be different according to the clinical conditions, disease location and geographical area. Alvimedica wants to be on the edge of innovation to help providing these patients the safest and most effective solutions".
We are a global innovator of unique interventional medical devices, committed to continuing the development and manufacturing of globally recognized and highly innovative product portfolios in both endovascular and interventional cardiology.
We create the highest quality devices and technologies that answer patients' unmet needs. Our teams are spread all around the world, with our main manufacturing plants in Italy and Turkey.
Our driving passion is to improve the quality of life through innovative technology, creating a better future by investing in both clinical research and product development.
We firmly believe that by working with todays' leading physicians we will create highly effective solutions that meet today's real unresolved patient needs. This collaboration is fundamental to us as a company, in order to present and discuss new treatment options.